Press Releases

09 October 2020

Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™

06 October 2020

Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US

23 August 2020

BARHEMSYS® (amisulpride injection) Launched and Commercially Available in the US for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV)

14 August 2020

Results of Placing

13 August 2020

Interim Results for the Six Months ended 30 June 2020

27 July 2020

Acacia Pharma Advances Preparations for US Launch of BARHEMSYS®

15 July 2020

Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

02 July 2020

Acacia Pharma Announces US FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation

01 June 2020

Acacia Pharma Announces Debt for Equity Swap with Cosmo Pharmaceuticals

07 April 2020

Alessandro Della Chà Appointed as Director of Acacia Pharma Group plc

12 March 2020

Acacia Pharma Announces Brief Extension of FDA Review Period for NDA for BYFAVO™  

02 March 2020

Acacia Pharma Announces Changes to its Officers and Board of Directors

02 March 2020

Results for the Year ended 31 December 2019

27 February 2020

Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)

24 January 2020

Acacia Pharma Wins BEL Small Company of the Year 2019

13 January 2020

Acacia Pharma Announces Planned CFO Succession

10 January 2020

Acacia Pharma Enters into Strategic In-licensing, Investment and Loan Transaction with Cosmo Pharmaceuticals N.V.